BioMarin Pharmaceutical
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. BioMarin Pharmaceutical's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15% to $2,419,226,000. The net income raised on $167,645,000 and profit margin reached 7%. Total operating expenses were $1,746,275,000.
Profit Margin
| 2014 | 751.04M | -133.96M | -17.84% |
|---|---|---|---|
| 2015 | 889.89M | -171.79M | -19.31% |
| 2016 | 1.11B | -630.21M | -56.43% |
| 2017 | 1.31B | -117.04M | -8.91% |
| 2018 | 1.49B | -77.21M | -5.18% |
| 2019 | 1.70B | -23.84M | -1.4% |
| 2020 | 1.86B | 854.02M | 45.9% |
| 2021 | 1.84B | -64.08M | -3.47% |
| 2022 | 2.09B | 141.56M | 6.75% |
| 2023 | 2.41B | 167.64M | 6.93% |
BMRN Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 2.41B | 2.09B | 1.84B | 1.86B | 1.70B | 1.49B | 1.31B | 1.11B | 889.89M | 751.04M |
Cost of revenue | 577.06M | 483.66M | 470.51M | 524.27M | 359.46M | 315.26M | 241.78M | 209.62M | 152.00M | 129.76M |
Gross profit | 1.84B | 1.61B | 1.37B | 1.33B | 1.34B | 1.17B | 1.07B | 907.23M | 737.88M | 621.27M |
Operating exp. | ||||||||||
Research and development | 746.77M | 649.60M | 628.79M | 628.11M | 715.00M | 696.32M | 610.75M | 661.90M | 634.80M | 461.54M |
Selling and marketing | 488.4M | 450.3M | 405.1M | 403.4M | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 1.74B | 1.57B | 1.45B | 1.43B | 1.47B | 1.34B | 1.21B | 1.11B | 1.01B | 781.66M |
Operating income | 194.44M | 57.54M | -60.01M | -96.26M | -125.45M | -123.52M | -14.7M | -803.42M | -110.70M | -92.89M |
Other income (expenses), net | -5.87M | 92.03M | -15.33M | -5.55M | 30.64M | 51.65M | -35.86M | -594.72M | -44.02M | -31.97M |
Income before tax | 188.56M | 149.57M | -75.35M | -42.32M | -94.81M | -142.70M | -35.87M | -831.05M | -154.72M | -124.86M |
Income tax expense | 20.91M | 8.01M | -11.27M | -901.42M | -70.96M | -65.49M | 81.16M | -200.84M | 17.07M | 9.10M |
Net income | 167.64M | 141.56M | -64.08M | 854.02M | -23.84M | -77.21M | -117.04M | -630.21M | -171.79M | -133.96M |
Earnings per share | ||||||||||
Basic EPS | 0.89 | 0.76 | -0.35 | 4.75 | -0.13 | -0.44 | -0.67 | -3.8 | -1.07 | -0.92 |
Diluted EPS | 0.87 | 0.75 | -0.35 | 4.53 | -0.13 | -0.44 | -0.67 | -3.79 | -1.07 | -0.92 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |